Biotech Cara Therapeutics closed up 7% after popping as much as 14% percent during the regular session on strong Phase 1 trial data for its chronic kidney …
source CNBC
This Biotech Popped 7% On Strong Trial Data
Biotech Cara Therapeutics closed up 7% after popping as much as 14% percent during the regular session on strong Phase 1 trial data for its chronic kidney …
source CNBC
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More